A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemiplimab will be determined, followed by an expansion stage. During the expansion patients will receive Cemiplimab alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.

Study Overview

• Status: Active, not recruiting
• Conditions: Renal Cell Carcinoma
• Intervention / Treatment: Biological: Pexastimogene Devacirepvec (Pexa-Vec); Biological: Cemiplimab

• Study Type: Interventional
• Enrollment (Actual): 89
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Bedford Park, Australia, SA5042
    • Site 2632 Flinders Medical Centre
• Korea, Republic of
  • Daegu, Korea, Republic of, 41404
    • Site 2612 Kyungpook National University Chilgok Hospital
  • Daejeon, Korea, Republic of, 35015
    • Site 2616 Chungnam National University Hospital
  • Gwangju, Korea, Republic of, 58128
    • Site 2618 Chonnam National University Hwasun Hospital
  • Incheon, Korea, Republic of
    • Site 2622 Gachon University Gil Medical Center
  • Pusan, Korea, Republic of, 49201
    • Site 2613 Dong-A University Hospital
  • Pusan, Korea, Republic of, 49241
    • Site 2619 Pusan National University Hospital
  • Seongnam, Korea, Republic of, 35015
    • Site 2617 CHA University, CHA Bundang Medical Center
  • Seongnam-si, Korea, Republic of, 13620
    • Site 2620 Seoul National University Bundang Hospital
  • Seoul, Korea, Republic of, 02841
    • Site 2615 Korea University Anam Hospital
  • Seoul, Korea, Republic of, 03722
    • Site 2610 Severance Hospital, Yonsei University Health System
  • Suwon, Korea, Republic of, 16499
    • Site 2623 Ajou University Hospital
  • Wŏnju, Korea, Republic of, 50612
    • Site 2625 Wonju Severance Christian Hospital
  • Yangsan, Korea, Republic of, 50612
    • Site 2624 Pusan National University Yangsan Hospital
• United States
  • California
    • Irvine, California, United States, 92868
      • Site 2644 University of California, Irvine
  • Florida
    • Miami, Florida, United States, 33136
      • Site 2641 University of Miami
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Site 2643 Washington University
  • Ohio
    • Columbus, Ohio, United States, 43201
      • Site 2646 The Ohio State University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic or unresectable clear cell renal cell carcinoma (ccRCC)

• Part 2 Arm D ONLY: Patients must be refractory to anti PD-1 or anti-PD-L1 (either as monotherapy or in-combination with other approved checkpoint inhibitors or targeted therapies according to their approved label) and patients must meet all of the following criteria:

  1. Received treatment of approved anti PD-1 or anti-PD-L1 (dosed per label of the country providing the clinical site) for at least 6 weeks. History of anti-PD-L1 only is not allowed.
  2. Progressive disease after anti PD-1 or anti-PD-L1 will be defined according to RECIST 1.1. The initial evidence of progressive disease is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented progressive disease, in the absence of rapid clinical progression. (This determination is made by the Investigator; the Sponsor will collect imaging scans for retrospective analysis. Once progressive disease is confirmed, the initial date of progressive disease documentation will be considered the date of disease progression).
  3. Documented disease progression within 12 weeks of the last dose of anti PD-1 or anti-PD-L1. Patients who were re-treated or on maintenance with anti-PD-1 or anti-PD-L1 will be allowed to enter the study as long as there is documented progressive disease within 12 weeks of the last treatment date.
• Naive to systemic therapy for RCC or have progressed after, or were intolerant of, prior systemic therapy.
• Measurable disease based on RECIST 1.1 criteria. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
• Karnofsky performance status of 70-100
• Age ≥20 years old (or appropriate age of consent for the region)
• Adequate hematological, hepatic, and renal function

Exclusion Criteria:

• Known significant immunodeficiency due to underlying illness (e.g., human immunodeficiency virus [HIV] / acquired immune deficiency syndrome [AIDS]) and/or immune-suppressive medication including high-dose corticosteroids
• Part 2 only: Arm A,B,C: Prior treatment with any anti-cancer immunotherapy, including therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (prior IL-2 or interferon allowed) . For Part 1: patients are excluded if they were intolerant to anti-PD-1 or anti-PD-L1 targeted therapies
• Major surgery within 4 weeks of study treatment (minor surgical procedures are allowed)
• Ongoing severe inflammatory skin condition requiring prior medical treatment
• History of eczema requiring prior medical treatment
• Tumor(s) invading a major vascular structure (e.g., carotid artery) or other key anatomical structure (e.g., pulmonary airway) OR viable central nervous system malignancy
• Clinically significant and/or rapidly accumulating ascites, pericardial and/or pleural effusions.
• Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months.
• Asymptomatic cardiovascular disease (current or past history) unless cardiology consultation and clearance has been obtained for study participation.
• Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all Pexa-Vec treatments
• Use of interferon/pegylated interferon (PEG-IFN) or ribavirin that cannot be discontinued within 14 days prior to any Pexa-Vec dose
• Known active Hepatitis B or Hepatitis C

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Part 1, Dose escalation; Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu. Cemiplimab will be administered via IV infusion every 3 weeks.	Biological: Pexastimogene Devacirepvec (Pexa-Vec); Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells; Other Names: JX-594; Biological: Cemiplimab; Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
EXPERIMENTAL: Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab; Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will be administered via IV infusion every 3 weeks.	Biological: Pexastimogene Devacirepvec (Pexa-Vec); Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells; Other Names: JX-594; Biological: Cemiplimab; Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
EXPERIMENTAL: Part 2-Arm B, Cemiplimab; Cemiplimab will be administered via IV infusion every 3 weeks. At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks.	Biological: Pexastimogene Devacirepvec (Pexa-Vec); Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells; Other Names: JX-594; Biological: Cemiplimab; Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
EXPERIMENTAL: Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab; Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks.	Biological: Pexastimogene Devacirepvec (Pexa-Vec); Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells; Other Names: JX-594; Biological: Cemiplimab; Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
EXPERIMENTAL: Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab; Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks.	Biological: Pexastimogene Devacirepvec (Pexa-Vec); Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells; Other Names: JX-594; Biological: Cemiplimab; Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose(MTD) / Maximum feasible dose (MFD)	MTD/MFD of Pexa-Vec administered by IV infusion in combination with Cemiplimab	36 days after first treatment
Severity and frequency of adverse events to determine safety of Pexa-Vec administered by IV infusions or IT injections in combination with IV Cemiplimab	Safety will be determined by assessing the severity and frequency of adverse events and laboratory toxicity using CTCAE v4.03	From date of first treatment until 28 days after last treatment
Overall response rate	Evaluate anti-tumor activity and efficacy of IV or IT Pexa-Vec combined with IV Cemiplimab with respect to overall response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1)	Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Progression free survival	Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months
Disease control rate	Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months
Best radiographic response	Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months
Overall survival	Every 9 weeks, then every 12 weeks after 1 year until date of death from any cause, up to 72 months

Collaborators and Investigators

• Sponsor: SillaJen, Inc.
• Collaborators: Regeneron Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 7, 2018
• Primary Completion (ANTICIPATED): August 1, 2023
• Study Completion (ANTICIPATED): November 1, 2023

Study Registration Dates

• First Submitted: September 19, 2017
• First Submitted That Met QC Criteria: September 21, 2017
• First Posted (ACTUAL): September 26, 2017

Study Record Updates

• Last Update Posted (ACTUAL): October 27, 2022
• Last Update Submitted That Met QC Criteria: October 26, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Cancer; Renal cell carcinoma; Clear cell renal cell carcinoma
• Additional Relevant MeSH Terms: Virus Diseases; Infections; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; DNA Virus Infections; Poxviridae Infections; Carcinoma, Renal Cell; Carcinoma; Vaccinia; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cemiplimab
• Other Study ID Numbers: JX594-REN026

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No